Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer

Published:2022-03 Issue:2 Volume:28 Page:96-104
ISSN:1540-336X
Container-title:The Cancer Journal
language:en
Short-container-title:Cancer J

Author:

Lu Shun,Yu Yan,Barnes Gisoo,Qiu Xiusong,Bao Yuanyuan,Tang Boxiong

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference22 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;CA Cancer J Clin,2018

2. Cancer statistics in China, 2015;CA Cancer J Clin,2016

3. Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011);J Thorac Dis,2012

4. Phase IA/IB study of single-agent tislelizumab, an investigational anti–PD-1 antibody, in solid tumors;J Immunother Cancer,2020

5. The symptom burden of non–small cell lung cancer in the USA: a real-world cross-sectional study;Support Care Cancer,2014

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of tislelizumab on health‐related quality of life in patients with recurrent or metastatic nasopharyngeal cancer;Head & Neck;2024-04-26

2. Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study;Liver Cancer;2024-02-21

3. Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients;Current Medical Research and Opinion;2023-11-23

4. Characteristics of clinical trials of new oncology drugs approved in China;Cancer;2023-11-20

5. The effects of tislelizumab treatment on the health‐related quality of life of patients with advanced non‐small cell lung cancer;Cancer Medicine;2023-08